Trujillo, Jonathan A. http://orcid.org/0000-0002-0184-9773
Luke, Jason J.
Zha, Yuanyuan
Segal, Jeremy P.
Ritterhouse, Lauren L.
Spranger, Stefani
Matijevich, Karen
Gajewski, Thomas F.
Funding for this research was provided by:
National Institutes of Health (2T32CA009566-31)
National Cancer Institute (R00CA204595, R35CA210098)
Article History
Received: 17 June 2019
Accepted: 22 October 2019
First Online: 8 November 2019
Ethics approval and consent to participate
: Biospecimens were obtained from patients who consented to participate in a biobank protocol to collect patient samples for future research. The Institutional Review Board of the University of Chicago approved the biobank protocol.
: Participants of the biobank protocol provide consent for data generated to be used in medical and scientific publications Patient names and personal identifying information are not disclosed and are removed before the use and publication of data.
: TFG: has received consultancy fees from Merck, Roche-Genentech, Abbvie, Bayer, Jounce, Aduro, Fog Pharma, Adaptimmune, FivePrime, and Sanofi. T.F.G. has received research support from Roche-Genentech, BMS, Merck, Incyte, Seattle Genetics, Celldex, Ono, Evelo, Bayer, Aduro. T.F.G. has intellectual property/licensing agreements with Aduro, Evelo, and BMS. T.F.G is a co-founder/shareholder with Jounce and Pyxis Oncology.JL: DSMB: TTC Oncology; SAB: 7 Hills, Actym, Alphamab Oncology, Array, BeneVir, Mavu, Tempest; Consultancy: Aduro, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Castle, CheckMate, Compugen, EMD Serono, IDEAYA, Immunocore, Janssen, Jounce, Merck, NewLink, Novartis, RefleXion, Spring Bank, Syndax, Tempest, Vividion, WntRx; Research Support: (clinical trials unless noted) AbbVie, Array (Scientific Research Agreement; SRA), Boston Biomedical, Bristol-Myers Squibb, Celldex, CheckMate (SRA), Compugen, Corvus, EMD Serono, Evelo (SRA), Delcath, Five Prime, FLX Bio, Genentech, Immunocore, Incyte, Leap, MedImmune, Macrogenics, Novartis, Pharmacyclics, Palleon (SRA), Merck, Tesaro, Xencor. Travel: Array, AstraZeneca, Bayer, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, IDEAYA, Immunocore, Janssen, Jounce, Merck, NewLink, Novartis, RefleXion Patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).SS: holds a patent on Wnt/β-catenin targeting to enhance anti-tumor immune responses (PCT15/155,099), serves on the SAB on Venn Therapeutics, Tango Therapeutics and consults for TAKEDA, Replimune, Ribon, Torque and Arcus.JPS: Honoraria: Bristol-Myers Squibb, AbbVie; Research Funding: AbbVie.LR: Honoraria: Bristol-Myers Squibb, AbbVie; Research Funding: AbbVie; Travel, Accommodations, Expenses: Bristol-Myers Squibb.JAT: declares no competing interests.YZ: declares no competing interests.KM: declares no competing interest.